Second Amendment to the Amended and Restated License Agreement made effective on March 1, 2010 between the Purdue Research Foundation and Endocyte, Inc. (“Agreement”)

Exhibit 10.2

Second Amendment to the Amended and Restated License Agreement made effective on March 1, 2010 between the Purdue Research Foundation and Endocyte, Inc. (“Agreement”)

This second amendment (“Amendment”), made and entered effective as of the 1st day of March, 2010 (the “Effective Date”) between Endocyte, Inc., with a place of business at 0000 Xxxx Xxxxxx, Xxxxx X0-000, Xxxx Xxxxxxxxx, XX 00000 (“Client”), and, Purdue Research Foundation, having a place of business at 0000 Xxx Xxxxxxxxx Xxxx., Xxxx Xxxxxxxxx, XX 00000.

WHEREAS, the name of the party Endocyte, Inc. is incorrectly referred to as “Endocyte Corporation” in the Agreement, the parties desire to amend the Agreement to correct the error and agree to the following amendments to the Agreement:

1. All references to “Endocyte Corporation” shall be amended to read “Endocyte, Inc.”

2. All other terms and conditions of the Agreement remain unchanged and in effect.

IN WITNESS WHEREOF, the undersigned, intending to be legally bound, have duly executed, or caused to be executed, this Amendment as of the Effective Date.  The undersigned further asserts that he/she possesses the actual authority to enter into this Amendment on behalf of his/her corporation or business entity.

Agreed to and Accepted:

Purdue Research Foundation Endocyte

By: _/s/ Xxxxx X. Najem___ __ By: __/s/ P. Xxx Ellis_ _________

   Signature Signature

______Emily X. Xxxxx        ____ _____P. Xxx Xxxxx            _________

Printed Name Printed Name

_____Corporate Counsel_ ____ ____President and CEO________

Title Title

________July 23, 2015__ ______ _____ July 23, 2015____________

Date Date